Abstract
Metoprolol, a highly cardioselective β-blocker without intrinsic sympathomimetic activity, continues to play an important role in current treatment guidelines for hypertension, chronic heart failure, and coronary artery disease. Experts pay special attention to its modern, slow-release pharmaceutical form in the form of succinate, thoroughly tested in a number of clinical trials. Metoprolol succinate can be used in a single daily dose which ensures high compliance. The paper presents typical clinical scenarios in which appropriately dosed metoprolol CR/XL should be used. It should be emphasized that metoprolol CR/XL has the most registration indications among all the original β-blockers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
